Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with l-Carnitine Improves Biocompatibility on Human Mesothelial Cells

Title: A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with l-Carnitine Improves Biocompatibility on Human Mesothelial Cells
Authors: Francesca Piccapane; Mario Bonomini; Giuseppe Castellano; Andrea Gerbino; Monica Carmosino; Maria Svelto; Arduino Arduini; Giuseppe Procino
Contributors: Piccapane, Francesca; Bonomini, Mario; Castellano, Giuseppe; Gerbino, Andrea; Carmosino, Monica; Svelto, Maria; Arduini, Arduino; Procino, Giuseppe
Publication Year: 2021
Collection: ARUd'A - Archivio Istituzionale della ricerca dell'università Chieti-Pescara (IRIS)
Subject Terms: Glucose‐sparing; L‐carnitine; Mesothelium; Peritoneal dialysi; Peritoneal dialysis solution; Xylitol
Description: The main reason why peritoneal dialysis (PD) still has limited use in the management of patients with end‐stage renal disease (ESRD) lies in the fact that the currently used glucose‐based PD solutions are not completely biocompatible and determine, over time, the degeneration of the peritoneal membrane (PM) and consequent loss of ultrafiltration (UF). Here we evaluated the biocompatibility of a novel formulation of dialytic solutions, in which a substantial amount of glucose is replaced by two osmometabolic agents, xylitol and L‐carnitine. The effect of this novel formulation on cell viability, the integrity of the mesothelial barrier and secretion of pro‐inflammatory cytokines was evaluated on human mesothelial cells grown on cell culture inserts and exposed to the PD solution only at the apical side, mimicking the condition of a PD dwell. The results were compared to those obtained after exposure to a panel of dialytic solutions commonly used in clinical practice. We report here compelling evidence that this novel formulation shows better performance in terms of higher cell viability, better preservation of the integrity of the mesothelial layer and reduced release of pro‐inflammatory cytokines. This new formulation could represent a step forward towards obtaining PD solutions with high biocompatibility.
Document Type: article in journal/newspaper
File Description: ELETTRONICO
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/33374405; info:eu-repo/semantics/altIdentifier/wos/WOS:000606095700001; volume:22; issue:1; firstpage:123; journal:INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; https://hdl.handle.net/11564/744917
DOI: 10.3390/ijms22010123
Availability: https://hdl.handle.net/11564/744917; https://doi.org/10.3390/ijms22010123; https://www.mdpi.com/1422-0067/22/1/123
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.B40DFA1D
Database: BASE